Progranulin Replacement Therapy for FTD — Vector Development and Validation

Progranulin Replacement Therapy for FTD — Vector Development and Validation

Background and Rationale

This clinical trial focuses on developing and validating progranulin replacement therapy for frontotemporal dementia (FTD) patients with GRN mutations, addressing the critical knowledge gap between progranulin deficiency and TDP-43 pathology. The study employs a novel adeno-associated virus (AAV9) vector system designed to deliver functional progranulin across the blood-brain barrier, targeting the lysosomal dysfunction that underlies FTD-GRN pathogenesis. The experimental approach includes comprehensive vector characterization, biodistribution studies, and dose-escalation safety evaluation in a first-in-human Phase I/II trial. Participants will be stratified by mutation type and disease stage, with primary endpoints focusing on CSF progranulin restoration and secondary measures including neuroinflammation markers (YKL-40, soluble TREM2) and lysosomal enzyme activity. The study incorporates advanced neuroimaging (11C-PK11195 PET for microglial activation) and fluid biomarkers to monitor target engagement and downstream effects on neurodegeneration.

...

Progranulin Replacement Therapy for FTD — Vector Development and Validation

Background and Rationale

This clinical trial focuses on developing and validating progranulin replacement therapy for frontotemporal dementia (FTD) patients with GRN mutations, addressing the critical knowledge gap between progranulin deficiency and TDP-43 pathology. The study employs a novel adeno-associated virus (AAV9) vector system designed to deliver functional progranulin across the blood-brain barrier, targeting the lysosomal dysfunction that underlies FTD-GRN pathogenesis. The experimental approach includes comprehensive vector characterization, biodistribution studies, and dose-escalation safety evaluation in a first-in-human Phase I/II trial. Participants will be stratified by mutation type and disease stage, with primary endpoints focusing on CSF progranulin restoration and secondary measures including neuroinflammation markers (YKL-40, soluble TREM2) and lysosomal enzyme activity. The study incorporates advanced neuroimaging (11C-PK11195 PET for microglial activation) and fluid biomarkers to monitor target engagement and downstream effects on neurodegeneration. This research represents a paradigm shift toward mutation-specific precision medicine in FTD, with potential applications for other lysosomal storage disorders and protein replacement strategies in neurodegeneration.

This experiment directly tests predictions arising from the following hypotheses:

• Cryptic Exon Silencing Restoration
• Cross-Seeding Prevention Strategy
• Axonal RNA Transport Reconstitution
• R-Loop Resolution Enhancement Therapy
• Blood-Brain Barrier SPM Shuttle System

Experimental Protocol

Phase 1: Participant recruitment and screening (months 1-6) of 60 presymptomatic GRN mutation carriers and 40 early symptomatic patients through established FTD research networks. Inclusion criteria: pathogenic GRN mutations, age 25-65, CDR≤0.5. Phase 2: Baseline assessments (months 7-9) including comprehensive neuropsychological battery, MRI with DTI sequences, lumbar puncture for CSF biomarkers (progranulin, TDP-43 species, neurofilament light), and TDP-43 PET imaging using [18F]PI-2620 tracer. Phase 3: Randomization and treatment (months 10-12) with intrathecal administration of AAV9-GRN vector (low dose: 1×10^12 vg, high dose: 3×10^12 vg) or placebo via lumbar puncture under fluoroscopic guidance. Phase 4: Follow-up assessments at months 1, 3, 6, 12, 18, and 24 post-treatment including monthly CSF progranulin monitoring for first 6 months, then quarterly. Safety monitoring includes complete blood counts, liver function tests, and AAV capsid antibody titers. Phase 5: Biomarker analysis using electrochemiluminescence immunoassays for progranulin quantification, single-molecule array technology for TDP-43 detection, and advanced MRI analysis including cortical thickness measurements and connectome mapping. Statistical analysis employs mixed-effects models for longitudinal data with correction for multiple comparisons.

Expected Outcomes

• Successful CNS transduction evidenced by 2-4 fold increase in CSF progranulin levels within 3 months post-treatment in high-dose group compared to placebo (p<0.001)
• Dose-dependent reduction in pathological TDP-43 species in CSF by 30-50% at 12 months, with high-dose group showing greater reduction than low-dose (p<0.01)
• Stabilization of cortical thinning rate in treated groups (<0.5% annual loss) compared to continued decline in placebo group (2-3% annual loss, p<0.05)
• Improved cognitive stability with <2-point decline on FTD-specific cognitive composite in treated groups vs 4-6 point decline in placebo at 24 months
• Reduced microglial activation on PET imaging showing 20-30% decrease in binding potential in treated participants compared to baseline by 18 months
• Acceptable safety profile with <10% serious adverse events and transient CSF pleocytosis resolving within 2 weeks in <30% of treated participants

Success Criteria

• • Achievement of sustained CSF progranulin levels >75% of normal range (>60 ng/mL) in ≥70% of high-dose treated participants
• • Statistically significant reduction in rate of cortical volume loss by ≥50% compared to natural history controls (p<0.05)
• • Measurable decrease in pathological TDP-43 biomarkers by ≥25% from baseline in treated groups at 12 months
• • No treatment-related serious adverse events leading to study discontinuation in >15% of participants
• • Demonstration of dose-response relationship between vector dose and both progranulin levels and clinical outcomes
• • Cognitive stabilization defined as <50% decline rate compared to historical controls on validated FTD assessment battery